



Published in final edited form as:

ACS Chem Biol. 2019 February 15; 14(2): 186–191. doi:10.1021/acscchembio.8b01079.

N*-Acyl L-homocysteine thiolactones are potent and stable synthetic modulators of the RhIR quorum sensing receptor in *Pseudomonas aeruginosa


Michelle E. Boursier^{1,†}, Joshua B. Combs^{1,‡}, and Helen E. Blackwell¹

¹Department of Chemistry, University of Wisconsin–Madison, 1101 University Ave., Madison, WI 53706, USA; blackwell@chem.wisc.edu

Abstract

The RhIR quorum sensing (QS) receptor in the pathogen *Pseudomonas aeruginosa* plays a prominent role in infection, and both antagonism and agonism of RhIR have been shown to negatively regulate important virulence phenotypes. Non-native lactone ligands are known to modulate RhIR activity, but their utility as chemical probes is relatively limited due to hydrolytic instability. Herein, we report our design and biological evaluation of a suite of hybrid AHL analogs with structures merging (1) features of reported lead RhIR ligands and (2) head groups with improved hydrolytic stabilities. The most promising compounds identified were *N*-acyl L-homocysteine thiolactones, which displayed enhanced stabilities relative to lactones. Moreover, they were highly selective for RhIR over another key QS receptor in *P. aeruginosa*, LasR. These compounds are amongst the most potent RhIR modulators known and represent robust chemical tools to dissect the complex roles of RhIR in the *P. aeruginosa* QS circuitry.

GRAPHICAL ABSTRACT



INTRODUCTION

Quorum sensing (QS) is a chemical signaling pathway that certain bacteria use to assess their local population densities and coordinate group behavior once a threshold cell number

[†]Current address: Promega Corporation, Fitchburg, WI 53711

[‡]Current address: Department of Chemistry, Yale University, New Haven, CT 06520

Electronic supplementary information (ESI) available

General chemical information, details of instrumentation and analytical methods, compound characterization data, and supplementary assay data.

is achieved (1). Gram-negative bacteria typically use *N*-acyl L-homoserine lactones (AHLs) as their QS signals, which are produced by LuxI-type synthases and sensed by cytoplasmic LuxR-type transcription factors (2). Upon ligand binding, LuxR-type receptors most commonly dimerize, bind to DNA, and regulate QS-associated genes. The opportunistic pathogen *Pseudomonas aeruginosa* utilizes a relatively complex QS system to regulate a host of virulence factors at high cell density. Two LuxI-type synthases, LasI and RhlI, produce *N*-(3-oxo-dodecanoyl) HL (OdDHL) and *N*-butyryl HL (BHL), respectively (Figure 1A) (3). These two signaling molecules are recognized by their cognate LuxR-type receptors, LasR and RhlR. OdDHL is also recognized by a third LuxR-type receptor, QscR, which has been found to both negatively regulate LasR and activate its own unique regulon of *P. aeruginosa* (4). LasR is generally considered to be at the top of the *P. aeruginosa* QS receptor hierarchy, as it regulates genes associated with other QS circuits (3). Due to this prominent role, LasR has been a primary target over the past ~15 years for the design of small molecule antagonists to block QS and reduce virulence in *P. aeruginosa* (5–10). However, there is increasing evidence that targeting RhlR with small molecule tools could be advantageous.

Our laboratory has recently shown that small-molecule activation and inhibition of RhlR can alter the expression levels of several different and important virulence factors in *P. aeruginosa*; for example, when RhlR is activated, pyocyanin production is reduced (7). In turn, when RhlR is inhibited, rhamnolipid production is decreased. Bassler and co-workers have shown that partial agonism of RhlR can reduce *P. aeruginosa* virulence in a *C. elegans* infection model (11), and very recently, that RhlR can also control certain virulence phenotypes via a yet to be identified ligand unique from BHL (12). To date, the most potent reported RhlR modulators contain homoserine lactone headgroups (i.e., agonist **S4** and antagonist **E22**, Figure 1A). We reported these two compounds in a comprehensive analysis of our non-native AHL libraries for RhlR modulators in 2015 (13). However, the hydrolytic instability of these ligands' lactone head groups is a drawback to their use as chemical probes, especially as *P. aeruginosa* culture media is observed to become more alkaline over time (14). Synthetic ligands for RhlR with enhanced stabilities over **S4** and **E22**, whilst maintaining their potencies, would be of significant utility to study QS pathways in *P. aeruginosa*.

In general, RhlR has seen far less scrutiny as a target for non-native ligand design relative to LasR in *P. aeruginosa*, largely due to its perceived smaller role in QS (see above (5, 6)). Interestingly, beyond our recent forays into the development of RhlR modulators (13, 17), most prior studies on synthetic RhlR ligands have actually involved AHL analogs with non-lactone headgroups. In 2003, Suga and co-workers investigated both BHL and OdDHL analogs that contained heterocyclic replacements for the lactone head group yet retained the native 4- or 12-carbon tail groups. The authors found that BHL variants with cyclopentanone and cyclohexanone head groups showed agonistic activity towards RhlR (**Suga-5**, **Suga-7**; Figure 1B (15)). Surprisingly, a 12-carbon OdDHL mimic with a cyclohexanone head group proved to be the most potent RhlR antagonist in this study (**Suga-3**; Figure 1B), suggesting the utility of longer tail groups in inhibiting RhlR. Later, Kato and co-workers found that a 10-carbon AHL analog with cyclopentyl head group (**C10-CPA**, Figure 1B) inhibits *P. aeruginosa* QS through the antagonism of both RhlR and LasR (16). More recently, Bassler

and co-workers reported that a *meta*-bromo aryl homocysteine thiolactone (i.e., **mBTL**; Figure 1B) was a RhIR partial agonist (11). Homocysteine thiolactones have been examined in AHL analogs previously (11, 18–22), but except for **mBTL**, have not been explored as modulators of RhIR. Together, these prior studies indicated that RhIR can accommodate non-lactone head groups (assuming these close AHL mimetics target the BHL-binding site) and that further research into such compound scaffolds could be fruitful for new ligand design.

Herein, we report our design and biological evaluation of a set of hybrid AHL analogs with structures merging (1) features of the most promising reported RhIR ligands and (2) head groups with improved hydrolytic stabilities. These studies revealed, to our knowledge, the most potent non-native RhIR agonist to be reported, along with a highly potent RhIR antagonist. Notably, these two compounds both contain homocysteine thiolactones, a head group that shows improved hydrolytic stability relative to homoserine lactone, and are selective for RhIR over the other key LuxR-type receptor in *P. aeruginosa*, LasR.

RESULTS AND DISCUSSION

Active compounds uncovered in our recent BHL structure-activity relationship (SAR) study (17) and previously published RhIR leads (Figure 1B), as well as structural motifs with enhanced hydrolytic stability, motivated our selection of head and tail groups for new ligand design. Our SAR study suggested that both cyclopentanone and homocysteine thiolactone BHL analogs were capable of RhIR agonism, consistent with the work of the Suga and Bassler labs, respectively (11, 15). In addition, we found that RhIR well tolerates additional bulk at or near the α -position of the acyl tail, as exemplified by cyclopentyl HL **S4**, isovaleryl HL **7**, and cyclobutyl HL **17** (Figure 2A), resulting in agonists exceeding the potency of BHL (17). We reasoned that combining these structural features could yield new RhIR agonists, and tested this hypothesis by uniting the cyclopentanone and homocysteine thiolactone head groups with either isovaleryl or cyclobutanoyl tails to give compounds **34–37** (Figure 2B). Building on the prior work of Kato (16) and with an eye toward the development of new RhIR antagonists, we coupled the cyclopentyl head group with the isovaleryl or cyclobutanoyl tails to yield derivatives **38** and **39** (Figure 2C). Also with a view toward RhIR antagonism, we combined the cyclopentyl, tetrahydrofurfuryl, and homocysteine thiolactone head groups with the 4-iodo aryl tail from our potent RhIR antagonist **E22** (Figure 2A (7, 13)) to provide compounds **40–42** (Figure 2C). These hybrid compounds were synthesized using standard amide coupling chemistry in modest to good yields (40–80%) and purified to >95% prior to biological testing (**41** generated as a racemic mixture; see Methods).

The compounds were evaluated for their ability to either agonize or antagonize RhIR using an *Escherichia coli* strain harboring a RhIR expression plasmid and a reporter plasmid that allowed for straightforward read-out of RhIR activity (Table S1; see Methods). Simultaneously, we also screened the compounds in an analogous *E. coli* reporter system for LasR to investigate their selectivity for RhIR over LasR (Table S2). In the RhIR agonism screen, compounds **34–37** proved highly active at 10 μ M and 1 mM, displaying greater than 50% activation at 10 μ M. In the RhIR antagonism screen, compounds **38** and **41** were

modest antagonists, while compound **42** was found to inhibit RhIR more than any other compound in this study at both 10 μ M (28% inhibition) and 1 mM (74% inhibition). Notably, all of the compounds were largely inactive in the LasR assays as either agonists or antagonists, highlighting the selectivity of these hybrid ligand classes for RhIR modulation over LasR. The four lead hybrid RhIR agonists (**34–37**) and three lead hybrid RhIR antagonists (**38**, **41**, and **42**) identified in these primary screens were submitted to dose-response analyses in the *E. coli* RhIR reporter to determine their potencies. The native RhIR ligand, BHL, along with four parent compounds from our previous studies (**7**, **17**, **S4**, and **E22**; Figure 2A (13, 17)) were included as controls to better assess relative compound potency and maximal activity (i.e., efficacy). The resulting EC₅₀ and IC₅₀ values for the compounds, along with their associated efficacies, are listed in Table 1.

Hybrid compounds **34–37** proved either equipotent (**34** and **36**) or more potent (**35** and **37**) agonists than the native RhIR ligand, BHL (Table 1). The homocysteine thiolactone derivatives were the most potent overall, with cyclobutanoyl derivative **35** equipotent to its parent lactone compound **17**, and more notably, isovaryl homocysteine thiolactone **37** displaying two-fold greater potency over its lactone variant **7** and our previous lead agonist **S4**. Thiolactone **37**, with an EC₅₀ of 463 nM in the *E. coli* reporter, represented the most potent RhIR agonist identified in this study.

In terms of RhIR antagonism, a homocysteine thiolactone derivative again was the most potent (aryl thiolactone **42**), showing potency comparable to its parent aryl lactone **E22** in the *E. coli* reporter (Table 1). This result is interesting, as a previous study with a pair of aryl lactone and thiolactone analogs in LasR were found to display opposite activities (i.e., antagonist and agonist), respectively. Mutagenesis and computational studies in LasR implicated a hydrogen bond between the homoserine lactone (or homocysteine thiolactone) carbonyl and a conserved Trp residue in the LasR ligand-binding site (Trp 60) to be important for tuning compound activity (23). RhIR contains an analogous Trp residue (Trp 68). Our results showing that both homocysteine thiolactone **42** and its lactone analog **E22** are strong RhIR antagonists suggest that this Trp hypothesis may not be accurate for RhIR, at least with this aryl ligand scaffold. Of the other two RhIR antagonists submitted to dose-response analyses, cyclopentyl derivative **38** proved the next most active, with a potency only slightly lower than thiolactone **42**, albeit with a significantly lower inhibition efficacy (32% vs. 81%, Table 1).

We next sought to determine if the activity profiles for the most potent compounds in the *E. coli* reporter would be maintained in RhIR's native background, *P. aeruginosa*. Active efflux, along with the presence of acylases and reduced overall permeability, has been shown to decrease the activity of AHLs in *P. aeruginosa* relative to *E. coli* (24). Agonists **34–37** and antagonist **42** were submitted to analogous dose-response assays in a *P. aeruginosa* RhIR reporter strain (see Methods). Compounds **34–36** maintained their strong potency profiles between the two different reporters (Table 1), while compound **37** demonstrated a ~5-fold lower potency in *P. aeruginosa* relative to *E. coli*. Still, the homocysteine lactone analogs **35** and **37** were the most potent agonists in *P. aeruginosa* (EC₅₀ values of 1.65 and 2.58 μ M, respectively), further underscoring the utility of this head group for potent RhIR agonism. This trend was continued for RhIR antagonism, with homocysteine lactone **42** maintaining

its strong potency and efficacy in *P. aeruginosa* (with 85% maximum inhibition, Table 1) and marking this compound as one of the most potent antagonists of RhIR reported to date.

We were intrigued that both our lead RhIR agonist (**35**) and our lead RhIR antagonist (**42**) in *P. aeruginosa* were homocysteine thiolactone derivatives, a trend that corroborated the strong activity reported by the Bassler lab for the thiolactone **mBTL** (11). We reasoned that these alternate headgroups could alter the hydrolytic stabilities of these derivatives relative to AHLs. Indeed, in a 2011 study we showed that certain homocysteine thiolactone derivatives have increased hydrolytic stabilities relative to AHLs in Luria-Bertani medium as monitored via a biosensor assay (21). To evaluate their stability in a more direct and quantitative assay, we elected to monitor the stability of homocysteine thiolactone **42** relative to its homoserine lactone homolog **E22** over time and at varying pH values (6–9) using HPLC and MS (see Methods). Interestingly, the homocysteine thiolactone displayed remarkable stability in this assay, with half-lives ranging from approximately 6 to 23 times longer than the half-lives of the homoserine lactone (Figure 3). The differences in half-lives for **42** vs. **E22** grew dramatically larger at pH 7 (e.g., 240 h vs. 10 h at pH 8, respectively).

The results of these stability studies for **42** and **E22** do not align with earlier reports supporting the thermodynamic favorability of alkyl thioester hydrolysis (25). However, thioesters are known to have slow rates of hydrolysis, and published rate constants have typically been for electronically activated thioesters (e.g., trifluorothioacetate (26)). In the compounds tested here, homocysteine thiolactone ring size may also play a crucial role in the observed hydrolysis rates. Previous studies comparing homocysteine thiolactones and homoserine lactones in water/acetone mixtures showed that homoserine lactones hydrolyze at a two-fold faster rate (27). The resulting γ -mercapto acids from homocysteine thiolactone hydrolysis also readily recyclize upon acid exposure, while thiolactones with larger ring sizes are far less likely to recyclize (28). The HPLC/MS data for **42** and **E22** (Figure 3) support these past reports on the kinetics of homocysteine thiolactone hydrolysis. We note that the *P. aeruginosa* reporter assay used in this study was six hours in length and the final pH did not exceed 7.6, suggesting hydrolysis has a negligible effect on the activities of **42** and **E22** in these experiments. Nevertheless, for assays performed over more extended periods of time (> 10 h), and in view of the increasing alkalinity of *P. aeruginosa* culture media over time (14) and the observed preference of certain bacterial lactonases for homoserine lactones over homocysteine thiolactones (18), we believe that our homocysteine thiolactone RhIR modulators (**35**, **37**, and **42**) should constitute physically robust probes for the study of *P. aeruginosa* QS in a variety of biologically relevant environments.

SUMMARY

Both antagonism and agonism of the RhIR receptor have been shown to negatively regulate important virulence phenotypes in *P. aeruginosa*. While prior chemical efforts have delivered synthetic ligands for RhIR, the most potent of these compounds are all lactone based and suffer from relatively low hydrolytic stability. We designed a suite of new compounds that integrated the structures of these lead compounds with alternate head groups, and evaluated them in cell-based reporter assays for RhIR activity. The most promising compounds identified contain homocysteine thiolactone head groups (**35**, **37**, and **42**), and this motif

showed improved hydrolytic stability relative to the homoserine lactone group. These new ligands were highly selective for RhlR over another key QS receptor in *P. aeruginosa*, LasR, and are active in the *P. aeruginosa* background. Homocysteine thiolactones **35**, **37**, and **42** represent some of the most potent RhlR modulators known and constitute new tools to investigate the role of RhlR in QS regulation. Furthermore, they underscore the potential utility of the thiolactone motif for the design of synthetic ligands for other LuxR-type receptors.

METHODS

Chemistry

AHLs and AHL analogs were synthesized and purified using our previously reported procedures (17, 29). See SI for details of instrumentation and full characterization data for new compounds.

Bacteriology

Bacteria were cultured in Luria-Bertani medium (LB) at 37 °C. Absorbance measurements were performed in 96-well microtiter plates and path length-corrected using a Biotek Synergy 2 plate reader running Gen 5 software (version 1.05). Bacterial growth was assessed by measuring absorbance at 600 nm (OD₆₀₀).

Bacterial strains and assay protocols

The bacterial reporter strains used for this study were (i) *E. coli* strain JLD271 (*sdia*) harboring the RhlR expression plasmid pJN105R2 and the *rhlI-lacZ* transcriptional fusion reporter pSC11-rhlI*, (ii) *E. coli* strain JLD271 (*sdia*) harboring the LasR expression plasmid pJN105L and the *lasI-lacZ* transcriptional fusion reporter pSC11, and (iii) *P. aeruginosa* strain PAO-JP2 (*lasIrhII*) harboring the *rhlI-gfp* transcriptional fusion reporter *phII-LVAgfp*. Miller assays and GFP fluorescence assays were performed in these reporters as previously described (17, 30).

Homocysteine thiolactone/homoserine lactone stability studies

Stability studies were performed as reported previously (30) with some minor modifications (see SI for method, MS data, and RP-HPLC traces).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.


ACKNOWLEDGMENT

Financial support for this project was provided by the NIH (R01 GM109403). M.E.B. was funded in part by the NSF through the UW–Madison Materials Research Science and Engineering Center (DMR-1121288). NMR facilities were supported by the NSF (CHE-0342998) and a gift from P. Bender. MS facilities were supported by the NSF (CHE-9974839).

REFERENCES

1. Whiteley M, Diggle SP, and Greenberg EP (2017) Progress in and promise of bacterial quorum sensing research, *Nature* 551, 313–320. [PubMed: 29144467]
2. Papenfort K, and Bassler BL (2016) Quorum sensing signal-response systems in Gram-negative bacteria, *Nat. Rev. Microbiol* 14, 576–588. [PubMed: 27510864]
3. Schuster M, and Greenberg EP (2006) A network of networks: quorum-sensing gene regulation in *Pseudomonas aeruginosa*, *Int. J. Med. Microbiol* 296, 73–81. [PubMed: 16476569]
4. Ding FM, Oinuma K-I, Smalley NE, Schaefer AL, Hamwy O, Greenberg EP, and Dandekar AA (2018) The *Pseudomonas aeruginosa* Orphan Quorum Sensing Signal Receptor QsCR Regulates Global Quorum Sensing Gene Expression by Activating a Single Linked Operon, *Mbio* 9, e01274–18. [PubMed: 30154259]
5. Welsh MA, and Blackwell HE (2016) Chemical probes of quorum sensing: from compound development to biological discovery, *FEMS Microbiol. Rev* 40, 774–794. [PubMed: 27268906]
6. Galloway WRJD, Hodgkinson JT, Bowden SD, Welch M, and Spring DR (2011) Quorum sensing in Gram-negative bacteria: small-molecule modulation of AHL and AI-2 quorum sensing pathways, *Chem. Rev* 111, 28–67. [PubMed: 21182299]
7. Welsh MA, Eibergen NR, Moore JD, and Blackwell HE (2015) Small Molecule Disruption of Quorum Sensing Cross-Regulation in *Pseudomonas aeruginosa* Causes Major and Unexpected Alterations to Virulence Phenotypes, *J. Am. Chem. Soc* 137, 1510–1519. [PubMed: 25574853]
8. Amara N, Gregor R, Rayo J, Dandela R, Daniel E, Liubin N, Willems HME, Ben-Zvi A, Krom BP, and Meijler MM (2016) Fine-Tuning Covalent Inhibition of Bacterial Quorum Sensing, *ChemBioChem* 17, 825–835. [PubMed: 26840534]
9. Amara N, Mashiach R, Amar D, Krief P, Spieser S. a. H., Bottomley MJ, Aharoni A, and Meijler MM (2009) Covalent inhibition of bacterial quorum sensing, *J. Am. Chem. Soc* 131, 10610–10619. [PubMed: 19585989]
10. Galloway WRJD, Hodgkinson JT, Bowden S, Welch M, and Spring DR (2012) Applications of small molecule activators and inhibitors of quorum sensing in Gram-negative bacteria, *Trends Microbiol* 20, 449–458. [PubMed: 22771187]
11. O’Loughlin CT, Miller LC, Siryaporn A, Drescher K, Semmelhack MF, and Bassler BL (2013) A quorum-sensing inhibitor blocks *Pseudomonas aeruginosa* virulence and biofilm formation, *Proc. Natl. Acad. Sci. U. S. A* 110, 17981–17986. [PubMed: 24143808]
12. Mukherjee S, Moustafa DA, Stergioula V, Smith CD, Goldberg JB, and Bassler BL (2018) The PqsE and RhlR proteins are an autoinducer synthase-receptor pair that control virulence and biofilm development in *Pseudomonas aeruginosa*, *Proc. Natl. Acad. Sci. U. S. A* 115, E9411–E9418. [PubMed: 30224496]
13. Eibergen NR, Moore JD, Mattmann ME, and Blackwell HE (2015) Potent and Selective Modulation of the RhlR Quorum Sensing Receptor by Using Non-native Ligands: An Emerging Target for Virulence Control in *Pseudomonas aeruginosa*, *ChemBioChem* 16, 2348–2356. [PubMed: 26460240]
14. Yates EA, Philipp B, Buckley C, Atkinson S, Chhabra SR, Sockett RE, Goldner M, Dessaux Y, Cámara M, Smith H, and Williams P (2002) *N*-acylhomoserine lactones undergo lactonolysis in a pH-, temperature-, and acyl chain length-dependent manner during growth of *Yersinia pseudotuberculosis* and *Pseudomonas aeruginosa*, *Infect. Immun* 70, 5635–5646. [PubMed: 12228292]
15. Smith KM, Bu Y, and Suga H (2003) Induction and Inhibition of *Pseudomonas aeruginosa* Quorum Sensing by Synthetic Autoinducer Analogs, *Chem. Biol* 10, 81–89. [PubMed: 12573701]
16. Ishida T, Ikeda T, Takiguchi N, Kuroda A, Ohtake H, and Kato J (2007) Inhibition of quorum sensing in *Pseudomonas aeruginosa* by *N*-acyl cyclopentylamides, *Appl. Environ. Microbiol* 73, 3183–3188. [PubMed: 17369333]
17. Boursier ME, Moore JD, Heitman KN, Shepardson-Fungairino SP, Combs JB, Koenig LC, Shin D, Brown EC, Nagarajan R, and Blackwell HE (2018) Structure–Function Analyses of the *N*-Butanoyl L-Homoserine Lactone Quorum-Sensing Signal Define Features Critical to Activity in RhlR, *ACS Chem. Biol* 13, 2655–2662. [PubMed: 30114353]

18. Janssens JCA, Metzger K, Daniels R, Ptacek D, Verhoeven T, Habel LW, Vanderleyden J, De Vos DE, and De Keersmaecker SCJ (2007) Synthesis of *N*-Acyl Homoserine Lactone Analogues Reveals Strong Activators of SdiA, the *Salmonella enterica* Serovar Typhimurium LuxR Homologue, *Appl. Environ. Microbiol* 73, 535–544. [PubMed: 17085703]
19. Schaefer AL, Hanzelka BL, Eberhard A, and Greenberg EP (1996) Quorum sensing in *Vibrio fischeri*: Probing autoinducer-LuxR interactions with autoinducer analogs, *J. Bacteriol* 178, 2897–2901. [PubMed: 8631679]
20. Chhabra SR, Stead P, Bainton NJ, Salmond GPC, Stewart GSAB, Williams P, and Bycroft BW (1993) Autoregulation of carbapenem biosynthesis in *Erwinia carotovora* by analogues of *N*-(3-oxohexanoyl)-L-homoserine lactone, *J. Antibiot* 46, 441–454. [PubMed: 8478262]
21. McInnis CE, and Blackwell HE (2011) Thiolactone modulators of quorum sensing revealed through library design and screening, *Bioorg. Med. Chem. Lett* 19, 4820–4828.
22. Styles MJ, and Blackwell HE (2018) Non-native autoinducer analogs capable of modulating the SdiA quorum sensing receptor in *Salmonella enterica* serovar Typhimurium, *Beilstein J. Org. Chem* 14, 2651–2664. [PubMed: 30410627]
23. Gerdt JP, McInnis CE, Schell TL, Rossi FM, and Blackwell HE (2014) Mutational Analysis of the Quorum-Sensing Receptor LasR Reveals Interactions that Govern Activation and Inhibition by Nonlactone Ligands, *Chem. Biol* 21, 1361–1369. [PubMed: 25242287]
24. Moore JD, Gerdt JP, Eibergen NR, and Blackwell HE (2014) Active efflux influences the potency of quorum sensing inhibitors in *Pseudomonas aeruginosa*, *ChemBioChem* 15, 435–442. [PubMed: 24478193]
25. Jencks WP, Cordes S, and Carriuolo J (1960) The Free Energy of Thiol Ester Hydrolysis, *J. Biol. Chem* 235, 3608–3614. [PubMed: 13789811]
26. Barnett R, and Jencks WP (1969) The Rates of Hydrolysis of Two Thiol Esters in Water, *J. Org. Chem* 34, 38–40.
27. Stevens CM, and Tarbell DS (1954) The Kinetics Of Basic Hydrolysis Of Some γ -Lactones And γ -Thiolactones In Aqueous Acetone, *J. Org. Chem* 19, 1996–2003.
28. Lin'kova MG, Kuleshova ND, and Knunyants IL (1964) Thiolactones, *Russ. Chem. Rev* 33, 493–507.
29. Morkunas B, Galloway WR, Wright M, Ibbeson BM, Hodgkinson JT, O'Connell KM, Bartolucci N, Della Valle M, Welch M, and Spring DR (2012) Inhibition of the production of the *Pseudomonas aeruginosa* virulence factor pyocyanin in wild-type cells by quorum sensing autoinducer-mimics, *Org. Biomol. Chem* 10, 8452–8464. [PubMed: 23014532]
30. O'Reilly MC, and Blackwell HE (2016) Structure-Based Design and Biological Evaluation of Triphenyl Scaffold-Based Hybrid Compounds as Hydrolytically Stable Modulators of a LuxR-Type Quorum Sensing Receptor, *ACS Infect. Dis* 2, 32–38. [PubMed: 26807436]






Figure 2. Chemical structures of AHLs and analogs thereof examined in this study. (A) Control compounds for comparison to new ligands. New analogs blending (B) agonist head/tail groups for predicted RhIR agonist generation or (C) agonist head/tail groups and antagonist head/tail groups for predicted RhIR antagonist generation. Compound numbering originates from our previous study (17).




Figure 3. Compound degradation data. Degradation profiles at varying pH values for (A) homocysteine thiolactone **42** and (B) homoserine lactone **E22** and resulting half-lives (C) as measured via HPLC. MS data reported in Table S3.

Table 1:

EC₅₀ and IC₅₀ values and efficacy data for AHL analogs in the *E. coli* and *P. aeruginosa* RhIR reporter strains.^a Data for control compounds shaded in grey.

Compound	<i>E. coli</i>			<i>P. aeruginosa</i>		
	EC ₅₀ (μM)	95% CI (μM) ^b	Max. RhIR Activation (%)	EC ₅₀ (μM)	95% CI (μM) ^b	Max. RhIR Activation (%)
34	5.94	4.19 – 8.41	93	7.35	5.26 – 10.3	96
35	1.72	1.34 – 2.21	110	1.65	1.24 – 2.21	90
36	7.58	5.80 – 9.90	100	11.24	7.41 – 17.1	96
37	0.463	0.336 – 0.640	93	2.58	1.86 – 3.56	91
BHL	8.95	5.86 – 13.7	100	8.08	6.09 – 10.7	100
7	1.02	0.67 – 1.55	110	1.42	1.08 – 1.86	94
17	1.78	1.37 – 2.31	100	1.41	1.14 – 1.74	96
S4	1.58	1.32 – 1.90	100	1.22	1.03 – 1.45	110
	IC ₅₀ (μM)	95% CI (μM) ^b	Max. RhIR Inhibition (%)	IC ₅₀ (μM)	95% CI (μM) ^b	Max. RhIR Inhibition (%)
38	26.7	10.1 – 71.0	32	–	–	–
41	>100	–	56	–	–	–
42	19.6	14.3 – 26.9	81	31.4	19.6 – 50.4	85
E22	17.3	12.1 – 24.6	74	23.9	16.6 – 31.6	96

^aSee Methods for assay details. For full dose response curves, see Figures S1–S4.

^bCI = confidence interval.